Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells

Anti-Cancer Drugs

Volumn 23, Issue 8, 2012, Pages 836-845

  Garg, Monika ^a   Madan, Jitender ^a   Pandey, Ravi Shankar ^b   Sardana, Satish ^a   Katyal, Anju ^c   Chandra, Ramesh ^c  

^a Hindu College   (India)

^b GURU GHASIDAS UNIVERSITY   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

apoptosis; cytotoxicity; doxorubicin; galactosylated gelatin nanovectors; pharmacokinetics and biodistribution

Indexed keywords

CASPASE 3; DOXORUBICIN; DRUG CARRIER; GALACTOSYLATED GELATIN; GELATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RELEASE; HEART; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL PROLIFERATION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; GALACTOSE; GELATIN; HEP G2 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; MALE; MICE; NANOSPHERES; PARTICLE SIZE; TISSUE DISTRIBUTION;

EID: 84864409919     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328351424f     Document Type: Article

References (31)

1. Bosch FX, Ribes J, D'iaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127:S5-S16. (Pubitemid 39423365)
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19:1893-1907.
3. Livraghi T, Mäkisalo H, Line PD. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011; 100:22-29.
4. Lee RT, Wang MH, Lin WJ, Lee YC. New and more efficient multivalent glyco-ligands for asialoglycoprotein receptor of mammalian hepatocytes. Bioorg Med Chem 2011; 19:2494-2500.
5. Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci USA 2011; 108:2426-2431.
6. Yang RS, Chang LW, Yang CS, Lin P. Pharmacokinetics and physiologically based pharmacokinetic modeling of nanoparticles. J Nanosci Nanotechnol 2010; 10:8482-8490.
7. Malam Y, Lim EJ, Seifalian AM. Current trends in the application of nanoparticles in drug delivery. Curr Med Chem 2011; 18:1067-1078.
8. Lepenies B, Yin J, Seeberger PH. Applications of synthetic carbohydrates to chemical biology. Curr Opin Chem Biol 2010; 14:404-411.
9. Zhang J, Li C, Xue ZY, Cheng HW, Huang FW, Zhuo RX, Zhang XZ. Fabrication of lactobionic-loaded chitosan microcapsules as potential drug carriers targeting the liver. Acta Biomater 2011; 7:1665-1673.
10. Zhao Q, Chen W, Chen Y, Zhang L, Zhang J, Zhang Z. Self-assembled viruslike particles from rotavirus structural protein VP6 for targeted drug delivery. Bioconjug Chem 2011; 22:346-352.
11. Tasic-Kostov M, Savic S, Lukic M, Tamburic S, Pavlovic M, Vuleta G. Lactobionic acid in a natural alkylpolyglucoside-based vehicle: assessing safety and efficacy aspects in comparison to glycolic acid. J Cosmet Dermatol 2010; 9:3-10.
12. Madan J, Kaushik D, Sardana S, Mishra DN. Effect of ciprofloxacin and chloramphenicol on humoral immune response elicited by bovine albumin encapsulated in niosomes. Yao Xue Xue Bao 2007; 42:905-910.
13. Madan J, Kaushik D, Sardana S, Mishra DN, Singh SK, Singh BK. Effect of ampicillin and chloroquine on humoral immune response elicited by bovine albumin encapsulated in liposomes. Acta Pharm 2008; 58:479-487.
14. Madan J, Dhiman N, Parmar VK, Sardana S, Bharatam PV, Aneja R, et al. Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics. Cancer Chemother Pharmacol 2010; 65:537-548.
15. Madan J, Kaushik D, Sardana S, Ali A, Sudhakaran MS, Pandey RS. Effect of levofloxacin and pefloxacin on humoral immune response elicited by bovine serum albumin docked in gelatin microparticles and nanoparticles. Pharmazie 2010; 65:284-289.
16. Chauhan R, Madan J, Kaushik D, Sardana S, Pandey RS, Sharma R. Inclusion complex of colchicine in hydroxypropyl-b-cyclodextrin tenders better solubility and improved pharmacokinetics. Pharm Dev Technol 2011. In press.
17. Pandey RS, Sahu S, Sudheesh MS, Madan J, Kumar M, Dixit VK. Carbohydrate modified ultrafine ceramic nanoparticles for allergen immunotherapy. Int Immunopharmacol 2011; 11:925-931.
18. Madan J, Dhiman N, Sardana S, Aneja R, Chandra R, Katyal A. Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. Anticancer Drugs 2011; 22:543-555.
19. Alvi IA, Madan J, Kaushik D, Sardana S, Pandey RS, Ali A. Comparative study of transfersomes, liposomes and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in vitro release and cytotoxicity analysis. Anticancer Drugs 2011; 22:774-782.
20. Brasiuniene B, Sokolovas V, Brasiunas V, Barakauskiene A, Strupas K. Combined treatment of uveal melanoma liver metastases. Eur J Med Res 2011; 16:71-75.
21. Blade J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, et al. Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk 2011; 11:44-49.
22. Riganti C, Voena C, Kopecka J, Corsetto PA, Montorfano G, Enrico E, et al. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 2011; 8:683-700.
23. Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI, Nel AE. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010; 4:4539-4550.
24. Mi FL, Wu YY, Chiu YL, Chen MC, Sung HW, Yu SH, et al. Synthesis of a novel glycoconjugated chitosan and preparation of its derived nanoparticles for targeting HepG2 cells. Biomacromolecules 2007; 8:892-898.
25. Fields R. The measurement of amino groups in proteins and peptides. Biochem J 1971; 124:581-590.
26. Gupta AK, Gupta M, Yarwood SJ, Curtis AS. Effect of cellular uptake of gelatin nanoparticles on adhesion, morphology and cytoskeleton organisation of human fibroblasts. J Control Release 2004; 95:197-207. (Pubitemid 38230035)
27. Crommelin DJA, Van Bloois L. Preparation and characterization of doxorubicin-containing liposomes. II. Loading capacity, long-term stability and doxorubicin-bilayer interaction mechanism. Int J Pharm 1983; 17: 135-144. (Pubitemid 14209361)
28. Ayen WY, Garkhal K, Kumar N. Doxorubicin-loaded (PEG) (3)-PLA nanopolymersomes: effect of solvents and process parameters on formulation development and in vitro study. Mol Pharm 2011; 8:466-478.
29. Jain A, Agarwal A, Majumdar S, Lariya N, Khaya A, Agrawal H, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 2010; 148:359-367.
30. Zhang C, Ping Q, Ding Y, Cheng Y, Shen J. Synthesis, characterization and microsphere formation of galactosylated chitosan. J Appl Polym Sci 2004; 91:659-665. (Pubitemid 38014265)
31. Maeda H, Noguchi Y, Sato K, Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. J Cancer Res 1994; 85:331-334. (Pubitemid 24129610)